OrbiMed Capital GP VI LLC, Director at Oric Pharmaceuticals, Inc. (ORIC), sold 65,880 shares at $26.47 ($1.7M) on 2021-03-19, disclosed to the SEC on 2021-03-23.
Scheduled sale ($1.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.47 | 21,275 | $563K | 32.6% |
| 2 | $26.47 | 21,275 | $563K | 32.6% |
| 3 | $26.47 | 7,673 | $203K | 11.8% |
| 4 | $26.47 | 7,673 | $203K | 11.8% |
| 5 | $24.32 | 3,992 | $97K | 5.6% |
| 6 | $24.32 | 3,992 |
| $97K |
| 5.6% |
| Total | $26.21 avg | 65,880 | $1.7M | 100% |
| Filing → |
| IRON | SELL | 2025-03-12 | $32.4M | — | Filing → |
| SCPH | BUY | 2024-08-15 | $2.0M | — | Filing → |
| NPCE | SELL | 2024-04-18 | $435K | — | Filing → |